Akkermansia Muciniphila Probiotics for Improved Gut Health

A composition for preventing or treating metabolic disorders, comprising pasteurized Akkermansia muciniphila and a green tea extract, for use in treating obesity, metabolic syndrome, insulin resistance, and other metabolic disorders. The composition is administered orally and can be used in food products, dietary supplements, or pharmaceuticals.

Source

A microbial combination for weight loss comprising Lactobacillus gasseri and Akkermansia muciniphila, with a specific ratio of 40-60 copies of each bacterium. The combination is prepared by culturing the bacteria in separate media and then combining them in a pharmaceutical composition for oral administration. The composition is used to treat obesity and related metabolic disorders, such as hypertension, hyperlipidemia, and diabetes.

Source

The gut microbiota is an indispensable component of the proper functioning of the human body, as gut microorganisms and their metabolites strongly influence the host's metabolism and immune functions. They also contribute to the biosynthesis of vitamins, production of gut hormones, maintenance of intestinal barrier integrity, protection against pathogens, as well as digestion and absorption of nutrients. Increasingly, the relationship between disturbances in the composition of gut microbiota and the onset of metabolic diseases such as obesity and type 2 diabetes is being emphasized. Understanding the significance of the microbiota in the course of these diseases, its composition, and activity may offer new approaches to their treatment. Increasing attention is being paid to individual species of gut bacteria, among which Akkermansia muciniphila holds a special position, as a decrease in the abundance of this commensal bacterium in the gut is associated with many diseases, including obesity and diabetes.

Source

A diet-reducing capsule containing multi-nutrient microspheres that simultaneously supports weight loss, nutritional supplementation, intestinal health, and probiotic colonization. The capsule combines hydrogel particles with probiotic-prebiotic-vitamin-mineral microspheres, which adhere to the hydrogel surface or are sandwiched between the particles. This microsphere matrix provides a stable environment for probiotic survival and absorption, while the hydrogel maintains its structure. The capsule is freeze-dried to preserve the microspheres' functionality, allowing them to release their active components over time. The combination of probiotics, vitamins, and minerals in the capsule provides a comprehensive nutritional support system for weight management, while the probiotics enhance gut health and satiety.

Source

Methods and compositions for treating weight-related disorders by altering the gut microbiota. The methods involve administering microbiota from specific bacterial phyla, orders, or genera to increase their relative abundance in the gut, thereby promoting weight loss and improving metabolic health. The compositions can include live bacterial strains or compounds that selectively increase or decrease specific microbiota populations. The methods can be used as a standalone treatment or in combination with other therapies, including surgery, to manage obesity and related metabolic disorders.

Source

A novel strain of Akkermansia muciniphila, designated as SSYD-3, for preventing and treating metabolic diseases. The strain exhibits improved fermentation performance, storage stability, acid and bile resistance compared to the existing ATCC BAA835 strain. It is effective in reducing visceral adipose tissue, improving oral glucose tolerance, and enhancing insulin sensitivity, making it a promising therapeutic agent for obesity, type 2 diabetes, and metabolic syndrome.

Source

A composition for improving intestinal microbial populations and reducing body weight, comprising galactose, which increases the proportion of beneficial bacteria such as Akkermansia, Lactobacillus, and Alistipes, and is used for preventing and treating obesity.

Source

The anaerobic bacterium Akkermansia muciniphila has demonstrated its role in regulating metabolism and markers of inflammation since its discovery. It is a Gram-negative bacteria that is classified within the phylum Verrucomicrobiae. It is recognized as a non-pathogenic bacteria, devoid of virulence factors and lacking a significant interaction with the host that leads to infection or disease. It is part of the human intestinal microbiome and its highest concentration is found in individuals of normal weight. A systematic review was performed to analyze clinical dietary interventions examining the association between obesity phenotype or status and the concentration of A. muciniphila in the intestinal microbiota, after specific nutritional modifications in overweight human patients. The search for articles was carried out using Pubmed and Clinicalkey as search engines. The Boolean terminology ((Akkermansia muciniphila) and (obesity)) and (intervention or nutrition or diet or nutrient) was used to select articles relevant to our research. Of the 301 original articles identified, only ... Read More

Source

The relationship between gut microbiota and obesity has recently been an important subject for research as the gut microbiota is thought to affect body homeostasis including body weight and composition, intervening with pro and prebiotics is an intelligent possible way for obesity management. To evaluate the effect of hypo caloric adequate fiber regimen with probiotic supplementation and physical exercise, whether it will have a good impact on health, body composition, and physique among obese Egyptian women or has no significant effect. The enrolled 58 women, in this longitudinal follow-up intervention study; followed a weight loss eating regimen (prebiotic), including a low-carbohydrate adequate-fiber adequate-protein dietary pattern with decreased energy intake. They additionally received daily probiotic supplements in the form of yogurt and were instructed to exercise regularly for 3 months. Anthropometric measurements, body composition, laboratory investigations, and microbiota analysis were obtained before and after the 3 months weight loss program. Statistically highly signifi... Read More

Source

Metabolic diseases are comprehensive disease based on obesity. Numerous cumulative studies have shown a certain correlation between the fluctuating abundance of Akkermansia muciniphila and the occurrence of metabolic diseases. A. muciniphila , a potential probiotic candidate colonized in the human intestinal mucus layer, and its derivatives have various physiological functions, including treating metabolic disorders and maintaining human health. This review systematically explicates the abundance change rules of A. muciniphila in metabolic diseases. It also details the high efficacy and specific molecules mechanism of A. muciniphila and its derivatives in treating obesity, type 2 diabetes mellitus, cardiovascular disease, and non-alcoholic fatty liver disease.

Source

Methods for treating metabolic disorders by administering a therapeutically-effective amount of a pharmaceutical composition comprising a population of isolated and purified microbes, wherein at least one of the microbes has a specific sequence identity to a rRNA sequence of a particular microbe species. The composition can comprise microbes that alter glucagon-like peptide-1 (GLP-1) production, encode for enzymes involved in butyrate production, or produce butyrate. The microbes can be selected based on their rRNA sequence identity to specific species, including Akkermansia muciniphilia, Anaerostipes caccae, and Bifidobacterium adolescentis.

Source

More than half of the states in the U.S. report that over 30% of adults are obese. Obesity increases the risk of many chronic diseases, including type 2 diabetes, hypertension, cardiovascular disease, and can even reduce ones lifespan. Similarly, the prevalence of type 2 diabetes follows a comparable trend. As a result, researchers are striving to find solutions to reduce obesity rates, with a particular focus on gut health, which has been previously linked to both obesity and type 2 diabetes. Recent studies suggest that Akkermansia muciniphila(AKK) may have a positive probiotic effect on preventing the onset of type 2 diabetes and obesity. We conducted a quantitative meta-analysis of 15 qualified animal studies investigating the effects of AKK administration as a probiotic. The statistical analyses showed that AKK administration significantly reduced body weight gain by 10.4% and fasting blood glucose by 21.2%, while also significantly improving glucose tolerance by 22.1% and increasing blood insulin levels by 26.9%. However, our analysis revealed substantial heterogeneity between ... Read More

Source

Abstract As one of the most attractive nextgeneration probiotics, mucindegrading Akkermansia muciniphila has emerged as an essential and integral factor in maintaining human health and affecting pathological outcomes. Its abundance is inversely associated with various metabolic diseases (e.g., obesity and type 2 diabetes), cardiovascular diseases, and intestinal inflammation. Supplementing A. muciniphila to restore the gut microbiota ecosystem is a promising approach for treating metabolic disorders. However, the direct utilization of this probiotic is limited by technological and regulatory hurdles, such as the in vitro bulk culture of A. muciniphila and the need for expensive animalderived materials. Therefore, enrichment of A. muciniphila using nutraceutical supplements is a feasible strategy. Dietary supplements, especially medicinal herbs, offer a vast and valuable resource as potential prebiotics for promoting the growth of A. muciniphila in the gut, ensuring reliable safety and efficacy. In this study, we first systemically reviewed the dietary substances and medicinal food... Read More

Source

In the present study, next generation probiotic Akkermansia muciniphila was incorporated into a dairy matrix containing Portuguese whey cheese and Greek-style yoghurt in a proportion of 3.5:1, respectively. Subsequently, this innovative food was characterized in terms of microbiological and physicochemical parameters, total phenolic content and antioxidant, antidiabetic, and antihypertensive activities, as well as its protective effect on A. muciniphila viability during 21 d of refrigerated aerobic storage and when subjected to simulated gastrointestinal passage. The probiotic cheese spread displayed high microbiological quality, low total phenolic content (0.36 mg gallic acid equivalents/g of dried cheese) and interesting biological activities, including antidiabetic (98.10% -glucosidase inhibition) and antihypertensive (49.18% angiotensin converting enzyme inhibition). Simultaneously, this food ensured a high A. muciniphila viability (>108 CFU/g) during 21 d of refrigerated aerobic storage with subsequent in vitro digestion. Additionally, this probiotic cheese presented a similar ... Read More

Source

A bacterium known as Akkermansia muciniphila (AkkermansiaA. muciniphila) was detected in human feces in 2004. It is defined as a gram-negative, anaerobic, and mucin-degrading microbe belonging to the Verrucomicrobia species. Although the majority of A. muciniphila is found in the human intestinal tract playing a role in the gut microbiome, there are also smaller levels detected in breast milk and oral cavities as well as in the pancreas and appendix.Evidence suggests that having A. muciniphila present in the gut microbiome has positive effects on human health. As a result, A. muciniphila has been shown to have health benefits when taken as a dietary supplementation where it is considered a promising next-generation probiotic. However, the large-scale production of A. muciniphila remains a challenge due to its need for a stable environment. While culturing A. muciniphila in a mucin-based medium is one option, other strategies that use plate-based mediums have also been explored. Currently, both live and pasteurized forms of A. muciniphila are available on the market and shown to have ... Read More

Source

Abstract Background The prevalence of excess weight and obesity is increasing in an extremely concerning manner worldwide, with highly diverse therapies for current treatment. This review evaluated the scientific evidence of the past 10 years on the use of probiotics in treating excess weight and obesity in the absence of dieting. Materials A systematic review was conducted by searching for clinical trials on humans published in English in the PubMed, Scopus and Cochrane Central databases, using the combination of keywords Overweight, Probiotics and Obesity, and published between 2012 and 2022. Results Six published studies met the inclusion criteria. The review showed that, although there is a lack of consensus in the literature, the use of probiotics in the absence of dieting produced a significant reduction in body weight and body mass index in 66.6% of the reviewed studies, a significant reduction in waist circumference in 80.0% of the reviewed studies, and an improvement in total body fat mass and waist circumference. Conclusions This review showed evidence of a trend in p... Read More

Source

Akkermansia muciniphila and Faecalibacterium prausnitzii are next-generation probiotics, which has been reported to protect disease and effectively utilize various carbohydrates (starch and pectin) as nutrients for growth. Atemoya exhibiting fruity flavor, which is suitable for enhancing aroma and attenuating unpleasant taste caused by the koji metabolites. Results indicated that malic acid was increased (from 42.4 to 70.1 mg/100 g) in fermented Atemoya-Amazake. In addition, fermented Atemoya-Amazake elevated growthes in A. muciniphila and F. prausnitzii. Similarly, the populations of Parabacteroides (5.7 fold) and Akkermansia (1.66 fold) were elevated by fermented Atemoya-Amazake treatment in an in vitro simulated gastrointestinal system compared to the control group. Results revealed that fermented Atemoya-Amazake modulated the intestinal microbiota through increasing the production of short-chain fatty acids (exhibiting anti-pathogenic activity) for 2.1, 2.5, 2.6, and 2.1 folds in acetic acid, propionic acid, isobutyric acid, and butyric acid, respectively; suggesting this ferment... Read More

Source

Obesity is a global health concern associated with a wide range of diseases, including diabetes, metabolic syndrome, fatty liver, and cardiovascular conditions. Recent studies highlight the significant role of gut microbiota in obesity. Research indicates notable changes in the composition and diversity of gut microbiota in individuals diagnosed with obesity. The gut microbiota participate in energy metabolism, lipid synthesis, and regulation of inflammation and therefore play a key role in the pathogenesis of obesity. Therapeutic approaches based on the use of probiotics, prebiotics, Akkermansia muciniphila, and fecal microbiota transplantation have shown promise in animal studies as useful strategies against obesity and metabolic syndrome. However, further research is warranted to conclusively establish the specific strains, dosages, and mechanisms underlying the effectiveness of these novel strategies against obesity in humans.

Source

Akkermansia muciniphila is a gram-negative anaerobic bacterium, which represents a part of the commensal human microbiota. Decline in the abundance of A. muciniphila among other microbial species in the gut correlates with severe systemic diseases such as diabetes, obesity, intestinal inflammation and colorectal cancer. Due to its mucin-reducing and immunomodulatory properties, the use of probiotics containing Akkermansia sp. appears as a promising approach to the treatment of metabolic and inflammatory diseases. In particular, a number of studies have focused on the role of A. muciniphila in colorectal cancer. Of note, the results of these studies in mice are contradictory: some reported a protective role of A. muciniphila in colorectal cancer, while others demonstrated that administration of A. muciniphila could aggravate the course of the disease resulting in increased tumor burden. More recent studies suggested the immunomodulatory effect of certain unique surface antigens of A. muciniphila on the intestinal immune system. In this Perspective, we attempt to explain how A. mucinip... Read More

Source

Compositions comprising at least one strain of Akkermansia muciniphila, characterized by diverse capsular types, biofilm formation, and activation of innate immune pathways, and methods of using these compositions to alter the gut microbiota and treat diseases such as obesity, metabolic disorders, and inflammatory conditions.

Source